About this trial
This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
Patient Profile
Patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St James’s Hospital, Tallaght University Hospital, University Hospital Limerick, University Hospital Galway, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | HOVON 156 |
|---|---|
| Number: | 19-16 |
| Full Title: | A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy |
| Principal Investigator: | Dr Janusz Krawczyk (University Hospital Galway) |
|---|---|
| Type: | Collaborative |
| Sponsor: | Collaborative Group Trial sponsored by HOVON (based in The Netherlands) |
| Recruitment Started: |
Global: December 2019 Ireland: May 2021 |
| Global Recruitment Target: | 768 |
|---|---|
| Ireland Recruitment Target: | 50 |